Our results suggest that drugs that prevent the increase in CD36 expression and/or CD36 from anchoring at the plasma membrane may alleviate NAFLD and prevent the transition from benign steatosis toward more advanced NASH. Here, CD36 is linked to metabolic dysfunction-associated steatohepatitis.